Foundation Medicine is a molecular insights company that provides information to physicians and their patients through a deep understanding of the molecular changes that contribute to diseases such as cancer.
Foundation Medicine offers a full suite of comprehensive genomic profiling (CGP) assays to identify the molecular alterations in an individual patient's cancer and match them with relevant targeted therapies, immunotherapies and clinical trials.
In New Zealand, Roche’s pharmaceutical division is the licensed distributor of FoundationOne®CDx and FoundationOne®Liquid CDx for patients with solid tumours, as well as FoundationOne®Heme for patients with sarcomas or haematological cancers including leukaemia, lymphoma and myeloma.
Cancer treatment has evolved to become as unique as your cancer. Now we have medicines that target unique genomic alterations driving your cancer - so we need to find out which targeted treatment is right for you.
For more information, visit
Healthcare professionals who would like more information about Roche Foundation Medicine services may go to
Orders may be placed by medical doctors through
© 2023, Roche Products (New Zealand) Ltd, Auckland. This site is intended for New Zealand audiences. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or use in the country of your origin. Access to this site is subject to the terms in our Legal and Privacy Statement. You accept these terms by continuing to access this site.
M-NZ-00000625-v6.0/MR9618/NOV23. This site was last updated NOV2023